Last update
4/18/2026
Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 2 Researches
7.5
USERS' SCORE
Good
Based on 1 Review
8.3
Supplement Facts
Serving Size: 1 Fish Softgel
Amount Per Serving
%DV
Calories
15
Total Fat
1.5 g
2%**
Cholesterol
<5 mg
1%
Vitamin D3 (as Cholecalciferol) (from Lanolin)
25 mcg (1,000 IU)
125%
Fish Oil Concentrate
1.2 g (1,200 mg)
†
Omega-3 Fatty Acids:
Eicosapentaenoic Acid (EPA)
600 mg
†
Docosahexaenoic Acid (DHA)
300 mg
†
Top Medical Research Studies
7
We examined the MITIGATE study, focusing on the effects of icosapent ethyl (IPE), a purified omega-3 fatty acid, in adults with cardiovascular disease at risk for viral upper respiratory infections.
With about 16,500 participants, this clinical trial compared IPE treatment against usual care. The goal was to see if IPE could lessen the severity and impact of viral infections over six months.
Unfortunately, there was no significant evidence found that IPE improved outcomes for upper respiratory infections in this group.
With about 16,500 participants, this clinical trial compared IPE treatment against usual care. The goal was to see if IPE could lessen the severity and impact of viral infections over six months.
Unfortunately, there was no significant evidence found that IPE improved outcomes for upper respiratory infections in this group.
Read More
8
We investigated whether feeding infants formula supplemented with docosahexaenoic acid (DHA) and arachidonic acid (ARA) could impact the development of allergies and respiratory illnesses until age three.
In a well-structured, randomized, double-blind study, we followed children who received either supplemented or nonsupplemented formulas during their first year of life. Our findings showed that those on the DHA/ARA formula had significantly lower chances of developing upper respiratory infections and common allergic diseases.
Notably, the DHA/ARA group experienced a delayed onset and reduced incidence of respiratory issues, indicating potential benefits of early nutrition on long-term health.
In a well-structured, randomized, double-blind study, we followed children who received either supplemented or nonsupplemented formulas during their first year of life. Our findings showed that those on the DHA/ARA formula had significantly lower chances of developing upper respiratory infections and common allergic diseases.
Notably, the DHA/ARA group experienced a delayed onset and reduced incidence of respiratory issues, indicating potential benefits of early nutrition on long-term health.
Read More
Most Useful Reviews
6
Effective supplement
I consistently take this omega. It has a good formulation and comes in a large package. My sister's blemishes have disappeared. I highly recommend it.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 2 Researches
7.5
- All Researches
8
We investigated whether feeding infants formula supplemented with docosahexaenoic acid (DHA) and arachidonic acid (ARA) could impact the development of allergies and respiratory illnesses until age three.
In a well-structured, randomized, double-blind study, we followed children who received either supplemented or nonsupplemented formulas during their first year of life. Our findings showed that those on the DHA/ARA formula had significantly lower chances of developing upper respiratory infections and common allergic diseases.
Notably, the DHA/ARA group experienced a delayed onset and reduced incidence of respiratory issues, indicating potential benefits of early nutrition on long-term health.
In a well-structured, randomized, double-blind study, we followed children who received either supplemented or nonsupplemented formulas during their first year of life. Our findings showed that those on the DHA/ARA formula had significantly lower chances of developing upper respiratory infections and common allergic diseases.
Notably, the DHA/ARA group experienced a delayed onset and reduced incidence of respiratory issues, indicating potential benefits of early nutrition on long-term health.
Read More
7
We examined the MITIGATE study, focusing on the effects of icosapent ethyl (IPE), a purified omega-3 fatty acid, in adults with cardiovascular disease at risk for viral upper respiratory infections.
With about 16,500 participants, this clinical trial compared IPE treatment against usual care. The goal was to see if IPE could lessen the severity and impact of viral infections over six months.
Unfortunately, there was no significant evidence found that IPE improved outcomes for upper respiratory infections in this group.
With about 16,500 participants, this clinical trial compared IPE treatment against usual care. The goal was to see if IPE could lessen the severity and impact of viral infections over six months.
Unfortunately, there was no significant evidence found that IPE improved outcomes for upper respiratory infections in this group.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.3
- All Reviews
- Positive Reviews
- Negative Reviews
6
Effective supplement
I consistently take this omega. It has a good formulation and comes in a large package. My sister's blemishes have disappeared. I highly recommend it.
Read More
Frequently Asked Questions
7
We examined the MITIGATE study, focusing on the effects of icosapent ethyl (IPE), a purified omega-3 fatty acid, in adults with cardiovascular disease at risk for viral upper respiratory infections.
With about 16,500 participants, this clinical trial compared IPE treatment against usual care. The goal was to see if IPE could lessen the severity and impact of viral infections over six months.
Unfortunately, there was no significant evidence found that IPE improved outcomes for upper respiratory infections in this group.
With about 16,500 participants, this clinical trial compared IPE treatment against usual care. The goal was to see if IPE could lessen the severity and impact of viral infections over six months.
Unfortunately, there was no significant evidence found that IPE improved outcomes for upper respiratory infections in this group.
8
We investigated whether feeding infants formula supplemented with docosahexaenoic acid (DHA) and arachidonic acid (ARA) could impact the development of allergies and respiratory illnesses until age three.
In a well-structured, randomized, double-blind study, we followed children who received either supplemented or nonsupplemented formulas during their first year of life. Our findings showed that those on the DHA/ARA formula had significantly lower chances of developing upper respiratory infections and common allergic diseases.
Notably, the DHA/ARA group experienced a delayed onset and reduced incidence of respiratory issues, indicating potential benefits of early nutrition on long-term health.
In a well-structured, randomized, double-blind study, we followed children who received either supplemented or nonsupplemented formulas during their first year of life. Our findings showed that those on the DHA/ARA formula had significantly lower chances of developing upper respiratory infections and common allergic diseases.
Notably, the DHA/ARA group experienced a delayed onset and reduced incidence of respiratory issues, indicating potential benefits of early nutrition on long-term health.
References
- Ambrosy AP, Malik UI, Thomas RC, Parikh RV, Tan TC, et al. Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE). Am Heart J. 2021;235:54. 10.1016/j.ahj.2021.01.018
- Birch EE, Khoury JC, Berseth CL, Castañeda YS, Couch JM, et al. The impact of early nutrition on incidence of allergic manifestations and common respiratory illnesses in children. J Pediatr. 2010;156:902. 10.1016/j.jpeds.2010.01.002
